Sinopharm Group 미래 성장

SEHK:1099 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	698,276	10,026	12,706	13,062	14
12/31/2025	650,544	9,223	12,286	12,432	16
12/31/2024	599,101	8,174	21,344	15,575	12
6/30/2024	590,346	8,653	16,768	19,506	N/A
3/31/2024	598,415	9,315	34,844	37,370	N/A
12/31/2023	596,570	9,054	14,889	17,173	N/A
9/30/2023	594,526	9,248	36,909	39,315	N/A
6/30/2023	591,626	8,936	9,660	11,931	N/A
3/31/2023	570,067	8,688	14,302	16,763	N/A
12/31/2022	552,148	8,526	18,648	20,964	N/A
9/30/2022	546,147	7,914	6,159	8,507	N/A
6/30/2022	533,403	7,870	492	2,783	N/A
3/31/2022	528,383	7,970	5,378	7,658	N/A
12/31/2021	521,051	7,759	7,081	9,308	N/A
9/30/2021	507,611	7,847	-13,311	-11,252	N/A
6/30/2021	501,770	7,874	8,743	10,983	N/A
3/31/2021	474,798	6,956	-12,001	-9,890	N/A
12/31/2020	456,415	7,187	9,099	11,155	N/A
9/30/2020	442,674	6,698	23,821	26,121	N/A
6/30/2020	427,372	6,174	2,304	4,522	N/A
3/31/2020	431,976	6,554	24,344	26,653	N/A
12/31/2019	425,273	6,251	16,417	18,777	N/A
9/30/2019	406,394	6,311	-5	2,113	N/A
6/30/2019	382,717	6,012	-224	1,744	N/A
3/31/2019	360,760	6,087	-5,010	-3,011	N/A
12/31/2018	344,526	5,834	392	3,654	N/A
9/30/2018	336,113	5,523	-9,906	-6,868	N/A
6/30/2018	334,060	5,606	-170	2,882	N/A
3/31/2018	318,414	5,083	N/A	-6,249	N/A
12/31/2017	308,354	5,572	N/A	3,209	N/A
9/30/2017	288,855	5,217	N/A	-19	N/A
6/30/2017	269,356	4,861	N/A	-3,247	N/A
3/31/2017	264,691	4,996	N/A	N/A	N/A
12/31/2016	258,388	4,635	N/A	9,258	N/A
9/30/2016	251,401	4,515	N/A	11,117	N/A
6/30/2016	244,414	4,394	N/A	12,975	N/A
3/31/2016	234,499	3,885	N/A	N/A	N/A
12/31/2015	228,673	3,772	N/A	13,412	N/A
9/30/2015	222,513	3,548	N/A	9,472	N/A
6/30/2015	216,353	3,323	N/A	5,533	N/A
3/31/2015	207,865	3,037	N/A	N/A	N/A
12/31/2014	200,131	2,875	N/A	5,561	N/A
9/30/2014	190,883	2,719	N/A	5,747	N/A
6/30/2014	181,635	2,564	N/A	5,933	N/A
3/31/2014	174,251	2,407	N/A	5,437	N/A
12/31/2013	166,866	2,250	N/A	4,941	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 1099 의 연간 예상 수익 증가율( 4.5% )이 saving rate( 2.3% 보다 높습니다. ).

수익 vs 시장: 1099 의 연간 수익( 4.5% ) Hong Kong 시장( 11.7% 보다 느리게 성장할 것으로 예상됩니다. 11.7% 연간).

고성장 수익: 1099 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 1099 의 수익(연간 5.8% ) Hong Kong 시장( 7.8% 보다 느리게 성장할 것으로 예상됩니다. 7.8% 연간).

고성장 수익: 1099 의 수익(연간 5.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 1099 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 7.7 %).

Sinopharm Group 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Recent updates

New minor risk - Financial position

Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Third quarter 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.64 in 3Q 2023)

Sinopharm Group Co. Ltd. to Report Nine Months, 2024 Results on Oct 25, 2024

Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Investor sentiment improves as stock rises 21%

Second quarter 2024 earnings released: EPS: CN¥0.73 (vs CN¥0.81 in 2Q 2023)

Sinopharm Group Co. Ltd. Announces Change in President

Sinopharm Group Co. Ltd. Announces Management Changes

Second quarter 2024 earnings released

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Sinopharm Group Co. Ltd. to Report First Half, 2024 Results on Aug 23, 2024

The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956

Sinopharm Group Co. Ltd. Declares Final Dividend for the Fiscal Year Ended December 31, 2023, Payable on 13 August 2024

Upcoming dividend of CN¥0.87 per share

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Sinopharm Group (HKG:1099) A Risky Investment?

Sinopharm Group Co. Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Dividend of CN¥0.87 announced

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Sinopharm Group Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Investor sentiment improves as stock rises 16%

Is Sinopharm Group (HKG:1099) A Risky Investment?

There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding

Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)

If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Third quarter 2023 earnings released: EPS: CN¥0.64 (vs CN¥0.70 in 3Q 2022)

Sinopharm Group Co. Ltd. to Report Nine Months, 2023 Results on Oct 27, 2023

Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief Supervisor

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive Director

New major risk - Financial position

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Sinopharm Group Co. Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Sinopharm Group Co. Ltd. Approves Final Dividend for the Financial Year End 31 December 2022, Payable on 14 August 2023

Upcoming dividend of CN¥0.82 per share at 3.4% yield

Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive Director

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Sinopharm Group Co. Ltd. Approves Board Appointments

Is Sinopharm Group (HKG:1099) A Risky Investment?

Third quarter 2022 earnings released

Sinopharm Group Co. Ltd. to Report Q3, 2022 Results on Oct 26, 2022

Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Second quarter 2022 earnings released

Sinopharm Group Co. Ltd. to Report First Half, 2022 Results on Aug 26, 2022

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Now 20% undervalued

Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Now 20% undervalued

Sinopharm Group Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2021, Payable No Later Than 23 August 2022

Upcoming dividend of CN¥0.75 per share

Sinopharm Group Co. Ltd. Announces Executive Changes

Sinopharm Group Co. Ltd. Announces Resignation of Deng Jindong as Member of Audit Committee and Remuneration Committee of Board

Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

Sinopharm Group Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 23 August 2022

Now 20% undervalued after recent price drop

Full year 2021 earnings: EPS misses analyst expectations

Sinopharm Group Co. Ltd. to Report Q1, 2022 Results on Apr 21, 2022

We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Sinopharm Group Co. Ltd., Annual General Meeting, Jun 23, 2022

A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Now 22% undervalued

Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns